Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.

NCT03213301 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Malignant Pleural Mesothelioma, Advanced

Interventions

DRUG: Lurbinectedin

Sponsor

Swiss Cancer Institute